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Background: Aberrant hypermethylation of gene promoter regions is a primary mechanism by which tumor
suppressor genes become inactivated in breast cancer. Epigenetic inactivation of the protein tyrosine phosphatase
receptor-type O gene (PTPRO) has been described in several types of cancer.
Results: We screened primary breast cancer tissues for PTPRO promoter hypermethylation and assessed potential
associations with pathological features and patient outcome. We also evaluated its potential as a breast cancer
biomarker. PTPRO methylation was observed in 53 of 98 (54%) breast cancer tissues but not in adjacent normal
tissue. Among matched peripheral blood samples from breast cancer patients, 33 of 98 (34%) exhibited methylated
PTPRO in plasma. In contrast, no methylated PTPRO was observed in normal peripheral blood from 30 healthy
individuals. PTPRO methylation was positively associated with lymph node involvement (P = 0.014), poorly
differentiated histology (P = 0.037), depth of invasion (P = 0.004), and HER2 amplification (P = 0.001). Multivariate
analysis indicated that aberrant PTPRO methylation could serve as an independent predictor for overall survival
hazard ratio (HR): 2.7; 95% CI: 1.1-6.2; P = 0.023), especially for patients with HER2-positive (hazard ratio (HR): 7.5; 95% CI:
1.8-31.3; P = 0.006), but not in ER + and PR + subpopulation. In addition, demethylation induced by 5-azacytidine led to
gene reactivation in PTPRO-methylated and -silenced breast cancer cell lines.
Conclusions: Here, we report that tumor PTPRO methylation is a strong prognostic factor in breast cancer. Methylation of
PTPRO silences its expression and plays an important role in breast carcinogenesis. The data we present here may provide
insight into the development of novel therapies for breast cancer treatment. Additionally, detection of PTPRO methylation
in peripheral blood of breast cancer patients may provide a noninvasive means to diagnose and monitor the disease.
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Breast cancer is one of the most common cancers among
women worldwide, and its incidence, unfortunately, con-
tinues to rise. Breast tumor is a heterogeneous disease de-
rived from different molecular subtypes and displaying
varied clinical behavior [1]. Considerable efforts have been
made to improve survival via early diagnosis and treat-
ment with targeted therapies [2]. However, the limited
success of current therapeutic modalities has led to calls* Correspondence: charlenesyli@126.com; 273334556@qq.com
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itional targeted therapies [3].
Promoter hypermethylation is a type of epigenetic alter-
ation associated with gene silencing. In cancer, many
tumor suppressor genes are inactivated in this way. Hyper-
methylation of key tumor suppressors is a key contributor
to breast tumorigenesis and acts in concert with genetic
alterations to drive disease progression [4]. Epigenetic
modifications of tumor DNA may have prognostic signifi-
cance for breast cancer patients and provide targets for
treatment because they are potentially reversible. Epigen-
etic changes may also serve as markers for early detection
of the disease. As an example, screening for RASSF1A
hypermethylation in serum has been proposed as a form
of surveillance to detect early stage breast cancer [5].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in better understanding the role of tyrosine phosphoryl-
ation in cancer [6-11], especially since this post-translational
modification helps regulate diverse cellular processes, in-
cluding proliferation, differentiation, metabolism, cell-to-cell
communication, transcription, and survival [12]. Phosphor-
ylation is a dynamic process that is positively regulated by
protein tyrosine kinases (PTKs) and negatively regulated by
protein tyrosine phosphatases (PTPs). More than 80% of on-
cogenes encode PTKs [13]; in contrast, many PTPs have
been described to function as tumor suppressors [14]. For
example, the tyrosine phosphatase PTPN2 activates TP53
and induces apoptosis in human tumor cells [15]. Another
phosphatase, PTP1B, negatively regulates insulin signaling
via dephosphorylation of insulin receptor kinase [16]. Com-
putational analysis of the human genome identified 38 clas-
sical PTP genes, 19 of which mapped to regions frequently
deleted in human cancers. Thirty of these protein phospha-
tases have been implicated in tumorigenesis [17], further
demonstrating their potential roles as tumor suppressors.
Protein tyrosine phosphatase receptor-type O (PTPRO)
is classified as a receptor-type PTP of the R3 subtype [18]
and exhibits characteristics of a tumor suppressor in mul-
tiple cancers [19]. Several PTPRO variants have been de-
scribed due to use of distinct transcriptional start sites and
to alternative splicing; while many lymphoid-derived cells
express a truncated PTPRO isoform, most epithelial tis-
sues, including the breast, express the full-length form
[19]. Previous studies have reported methylation-mediated
down-regulation of PTPRO expression in breast cancer
and other tumor types, such as rat hepatocellular carcin-
oma, human chronic lymphocytic leukemia, human lung
cancer, esophageal carcinoma [6-11,20]. Hypermethylation
of PTPRO occurs frequently in esophageal carcinoma and
may be a potential biomarker of the disease [20]. A recent
study also revealed that acute lymphoblastic leukemia pa-
tients with PTPRO methylation showed increased rates of
relapse and chemoresistance [9].
More recently, a tumor suppressive role for PTPRO in
breast cancer has emerged. Tumor-specific PTPRO pro-
moter methylation was documented in primary human
breast cancer cases [10]. The authors of this study also
found that PTPRO expression was reduced upon treat-
ment with estrogen but increased by treatment with the
anti-estrogen Tamoxifen. Furthermore, ectopic expression
of PTPRO in non-expressing MCF-7 cells sensitized them
to the growth suppressive effects of Tamoxifen. PTPRO
methylation has been further confirmed to be clinically
relevant in breast cancer, particularly in HER2-amplified
patients. Huang et al. showed that overall survival is sig-
nificantly worse in HER2-positive patients with methylated
PTPRO compared to tumors lacking methylation of this
promoter region [21]. Another study found that low ex-
pression of PTPRO correlated with reduced survival forHER2-positive breast cancer patients [11]. It is possible
that the pronounced impact of PTPRO specifically in
HER2-positive disease could be due to the fact that HER2
itself is a direct substrate of PTPRO phosphatase activity
[11]; specifically, loss of PTPRO was shown to increase
HER2 phosphorylation and HER2-induced proliferation
and transformation of breast cancer cell lines. Taken to-
gether, these data support a role for PTPRO as a tumor
suppressor in breast cancer and suggest that its methyla-
tion and expression may have prognostic significance in
the disease.
In the current study we investigated the methylation sta-
tus of PTPRO in primary human breast cancer from fresh
frozen specimens with the aim of defining the frequency
of this epigenetic aberration in the disease. We examined
the methylation status of PTPRO in primary breast tumors
and matched peripheral blood samples and determined if
promoter methylation was associated with decreased gene
expression in breast cancer cell lines. We also examined
associations between PTPRO methylation and several clin-
icopathological parameters, including patient outcome.
Methods
Tumor samples
Between 2006 and 2009, we obtained 98 tumor samples
and matched pre-operative peripheral blood samples from
women undergoing surgery for primary invasive breast car-
cinoma at ShenZhen Maternal and Child Health Hospital,
an affiliate of Southern Medical University in China. None
of the patients had received any pre-operative treatment,
including chemotherapy or radiotherapy. This is a well-
characterized series of patients under the age of 74 years
(median, 46 years). The median follow-up time of patients
in the study was 60 months (range 43–70 months). All pa-
tients were treated uniformly at a single institution.
Pathologic characteristics, including histological grade,
histological tumor type, tumor size, and lymph node in-
volvement were routinely assessed; several patient charac-
teristics, including age and family history of cancer and
menopause, were also recorded. Survival data were main-
tained prospectively. At the end of the study period, 39
(40%) patients had died because of disease recurrence. In
total, 98% of node-positive and 82% of node-negative pa-
tients received adjuvant systemic therapy consisting of ei-
ther hormone therapy alone or hormone therapy plus
chemotherapy.
Tumor samples were immediately frozen in liquid nitro-
gen and stored at −80°C until use. All tumors were con-
firmed histopathologically and their clinical features were
classified based on the TNM system of the International
Union Against Cancer [22]. Corresponding adjacent non-
cancerous tissues were also obtained from surgical resec-
tions. Peripheral venous blood samples from breast tumor
patients were collected in EDTA-containing tubes and
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plasma. The plasma samples were stored at −80°C until
further processing. Peripheral blood samples from an add-
itional 30 healthy volunteers were used as normal controls.
Estrogen receptor (ER), progesterone receptor (PgR), and
human epidermal growth factor receptor 2 (HER2) immu-
nohistochemistry was performed on TMA sections as pre-
viously described [23].
Approval for the use of human tissues and clinical infor-
mation was obtained from the Committee for Ethical Re-
view of Research involving Human Subjects at Southern
Medical University. All patients provided written informed
consent for sample collection prior to surgery.
Cell culture and treatment
Human breast cancer cell lines MCF-7, MDA-MB-231,
and Hs578t (provided by Dr. Qi T. Yan, Southern Medical
University, Guangzhou, China), were maintained in
DMEM supplemented with 5% fetal bovine serum and
1 mM nonessential amino acids in a 5% CO2 incubator.
Normal human mammary epithelial cells (HMEC 48R;
provided by Dr. Qi T. Yan, Southern Medical University,
Guangzhou, China) were maintained in MEGM (Cambrex
Corp., USA) as previously described [10]. To confirm that
methylation of the PTPRO promoter in breast cancer cell
lines was responsible for its suppression, MCF-7 and
MDA-MB-231 cells were treated with 5-azacytidine (5-
AzaC, Sigma Chemical Co., HK), a DNA-hypomethylating
agent, according to the following conditions: 1 μmol/L
for 72 h for MCF-7 cells, and 2.5 μmol/L for 96 h for MDA-
MB-231 cells. The response of different cell lines to demethy-
lating agents probably varies due to different drug sensi-
tivities as well as different kinetics of association/
dissociation of chromatin remodelers with specific
genes. All cells used in this study were between pas-
sages 8 and 11.
DNA extraction and bisulfite modification
Genomic DNA from primary tumors and plasma was ex-
tracted using a QIAamp DNA Mini Kit (Qiagen, Germany)
and QIAamp DNA blood Mini Kit (Qiagen, Germany).
Gene methylation status was evaluated using sodium bisul-
fite modification of DNA and subsequent methylation-
specific PCR (MSP), essentially as previously described
[24-26]. DNA (1–2 μg) from each sample was subjected to
bisulfite modification using EpiTect 96 Bisulfite Kits ac-
cording to the manufacturer’s instructions (Qiagen,
Germany). Bisulfite-modified DNA was typically immedi-
ately used for PCR.
Methylation-specific PCR analysis
Primer sequences for PCR amplification of methylated
and unmethylated alleles of PTPRO were previously
published [10] and are listed in Table 1. Primers weresynthesized by Shenggong (Shenggong Biotech, Shang-
hai, China). Primers were designed to amplify 170 bp
(methylated) or 201 bp (unmethylated) regions of the
CpG island within the PTPRO promoter [8]. For each re-
action, 3 μl of sodium bisulfite- converted DNA was added
to a total volume of 50 μl of PCR mix (EpiTect MSP Kits,
Qiagen, Germany) according to the manufacturer’s in-
structions. Briefly, samples were initially incubated at 95°C
for 10 min. This was followed by 35 cycles of denaturation
at 95°C for 15 s, annealing at 55°C for 30 s, and extension
at 72°C for 30 s; finally, there was one round of extension
at 72°C for 10 min. An additional 15 cycles of denaturing
(30 s at 94°C), annealing (15 s at 50.4°C), and extension
(30 s at 72°C) were required for blood samples. PCR prod-
ucts were analyzed by electrophoresis on 2% agarose gels.
Primers for unmethylated PTPRO (Table 1) were used to
confirm the presence of DNA in each sample following bi-
sulfite modification. This control was run for each sample
on the same day that MSP analysis was carried out for the
PTPRO gene. Breast tumor samples previously identified
as DNA hypermethylated were used as positive controls.
For each PCR assay, experimental reactions were accom-
panied by a black reaction (no DNA), a negative control
reaction (blood DNA), and a positive control reaction
(breast cancer DNA).
Bisulfite genomic sequencing
Bisulfite-converted DNA was used to PCR amplify the
PTPRO CpG island from -208 bp to +236 bp with respect
to the transcription start site as described earlier; ref.
[7,8,19]. The PCR product was purified using a gel extrac-
tion kit (Qiagen, Germany). The purified PCR product
was used for bisulfite sequencing and was cloned into the
pDrive vector according to the instructions of the PCR
cloning kit (Qiagen, Germany). Ten randomly selected
clones were subjected to automated sequencing. Direct se-
quencing was performed using the Thermo Sequenase
Radiolabeled terminator cycle sequencing kit (Qiagen,
Germany) with the primer hGlepp1-BS-F3 (5′-TAGGGG
GATTGGAAAGGTAG-3′) following the manufacturer’s
protocol.
RNA isolation and reverse transcription PCR analysis
Total RNA was isolated using the RNeasy Mini kit (Qiagen,
Germany). Reverse transcription of deoxyribonuclease-
treated RNA (1 μg) was carried out according to instruc-
tions provided with the QuantiTect Reverse Transcription
kit (Qiagen, Germany). Semi-quantitative PCR for PTPRO
expression was performed. 0.2 mM of each primer was
added to a 25 μl PCR reaction mixture. Cycling conditions
were as follows: denaturation at 94°C, annealing at 54.5°C
(for PTPRO) or 65°C (for 18S rRNA), and extension at 72°C.
For PTPRO, a total of 32 cycles were run, and for18S rRNA,
25 cycles were used. The PCR products were separated on
Table 1 PCR primer sequences for methylation analysis of PTPRO
Primers Sequences Product size
PTPRO-forward 5′-CTCCACCCAAATCACTCTTCGCAG-3′ 268 bp
PTPRO-reverse 5′-ACCATTGTTGAGACGGCTATGAACG-3′
18 s rRNA-forward 5′-TCAAGAACGAAAGTCGGAGG-3′ 110 bp
18 s rRNA- reverse 5′-GGACATCTAAGGGCATCACA-3′
MSP-methylated-forward 5′-CGTTTTTGGAGGATTTCGGGC-3′ 170 bp
MSP-methylated- reverse 5′-AAAACACGACTACGCTAACG-3′
MSP-unmethylated-forward 5′-ATGTTTTTGGAGGATTTTGGGT-3′ 201 bp
MSP-unmethylated- reverse 5′-ATACCCCATCACTACACAAACA-3′
Table 2 Association of methylation of PTPRO gene





M 29 24 53
U 4 41 45
Total 33 65 98
M: Methylated; U: Unmethylated.
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under UV light using Bio-rad Quantity One software. 18S
rRNA transcripts in each sample were also amplified as in-
ternal controls for normalization. Gene-specific primers used
for amplification of PTPRO and 18S rRNA are listed in
Table 1.
Statistical analysis
The χ2 test was used to determine associations between
methylation of PTPRO and various phenotypic or molecu-
lar features of breast cancer. Fisher’s exact test was used
when individual cell numbers were less than 5. All P
values were derived from two-tailed statistical tests and
significance was assumed at P < 0.05. Kaplan–Meier ana-
lysis was used to assess cumulative survival probabilities,
and differences were evaluated using the log-rank test.
Multinominal logistic regression analyses were used to as-
sess the hazard model for the survival of breast cancer pa-
tients. All analyses were performed using the SPSS 19.0
(Chicago, IL, US) statistical software package.
Results
Frequent methylation of PTPRO in primary tumors and
peripheral blood samples
Methylation of the PTPRO promoter has been demon-
strated in different tumor types, including breast cancer
[7,8,10]. These observations, along with the growth-
suppressive properties not only of PTPRO [7,8] but of PTPs
in general [27], prompted us to further investigate PTPRO
methylation status in a large series of human breast tumors.
Genomic DNA isolated from tumor tissue, surrounding
normal tissue, and matched peripheral blood samples (n =
98) was subjected to MSP analysis. Among the 98 primary
breast tumor specimens investigated, 53 (54%) showed
hypermethylation of PTPRO. Methylation of this gene was
not observed in any adjacent normal tissues. 33 of 98 (34%)
patients exhibited detectable levels of methylated PTPRO in
matched plasma. No methylated PTPRO was observed in
normal peripheral blood samples from 30 healthy individ-
uals. The χ2 test revealed that PTPRO methylation in
plasma was significantly correlated to that in tumor tissue(r= 0.435; P < 0.0001, Table 2). Representative MSP results
from primary tumors are shown in Figure 1a, b.
Clinicopathological significance of PTPRO methylation in
breast tumors and peripheral blood samples
Associations between PTPRO methylation and clinico-
pathological and molecular features of breast tumors in
this study are shown in Table 3. The strongest correlation
was between PTPRO methylation and HER2 amplification
(P = 0.001). PTPRO methylation was also significantly
more frequent in node positive (P = 0.014), poorly differ-
entiated (P = 0.037), and stage III (P = 0.004) tumors. The
highest frequency of PTPRO methylation (84%) was seen
in late stage tumors. Trends were also observed for more
frequent PTPRO methylation in ER- and PR-negative tu-
mors but no associations were apparent with patient age,
tumor size, histological tumor type, or TP53 mutation.
Methylation of PTPRO in plasma was more frequent in
those with HER2 amplification (P = 0.018). For all other
clinical and pathological parameters, there was no statisti-
cally significant correlation associated with methylation of
PTPRO in plasma (Table 3).
Prognostic significance of tumor tissue and plasma
PTPRO methylation
Univariate analysis examined clinicopathologic parameters
including PTPRO methylation and their association with
overall survival end points. The results showed that survival
was significantly worse in patients with lymph node in-
volvement (P = 0.0001), late stage tumors (P = 0.0001),
poorly differentiated tumors (P = 0.033), larger tumors (P =
Figure 1 Representative MSP results for methylation of the PTPRO gene. (a) primary breast tumors; (b) matched peripheral blood samples.
Numbers indicate the sample number. B, blank (no DNA); N, negative control; P, positive control; M, methylated; U, unmethylated.
Table 3 Associations between PTPRO methylation and clinicopathological features of breast cancer
Characteristics No. PTPRO methylation
Tumor tissue (%) χ2 P value plasma (%) χ2 P value
Total 98 53 (54) 33 (34)
Age
< 45 years 45 22 (49) 16 (36)
≥ 45 years 53 31 (59) 0.903 0.417 17 (32) 0.132 0.716
Nodal involvement
Negative 61 27 (44) 18 (30)
Positive 37 26 (70) 6.273 0.014 15 (40) 0.935 0.334
Stage
I/II 79 37 (47) 24 (30)
III 19 16 (84) 8.616 0.004 9 (47) 1.979 0.159
Histological type
Non-ductal 23 12 (52) 7 (30)
Ductal 75 41 (55) 1.000 0.510 26 (35) 0.141 0.707
Tumour size
≤20 mm 47 26 (55) 12 (26)
>20 mm 51 27 (53) 0.056 0.842 21 (40) 2.234 0.135
Histological grade
Well/mod diff. 60 27 (45) 18 (30)
Poorly diff. 38 26 (68) 5.139 0.037 15 (40) 0.935 0.334
ER status
Negative 24 16 (67) 10 (42)
Positive 74 37 (50) 2.027 0.167 23 (31) 0.909 0.340
PR status
Negative 29 20 (69) 10 (35)
Positive 69 33 (48) 3.674 0.076 23 (33) 0.012 0.912
HER2 status
Normal 51 19 (37) 12 (24)
Amplified 47 34 (72) 12.124 0.001 21 (46) 5.570 0.018
TP53 status
Normal 59 30 (51) 17 (29)
Mutant 39 23 (59) 0.624 0.535 16 (41) 1.568 0.211
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http://www.biomedcentral.com/1471-2156/15/670.019), positive HER2 amplification (P = 0.022), TP53 muta-
tion (P = 0.012) and PTPRO methylation (hazard ratio
(HR): 3.8; 95% CI: 1.9-7.5; P = 0.0001; Table 4). We then
stratified all patients into subpopulations according to ER,
PR and HER2 status. In ER- positive, PR- positive and
HER2-positive patients, the methylated PTPRO group
show significantly worse overall survival compared to those
of unmethylated PTPRO (P = 0.001, P = 0.012 and P =
0.010, respectively, Table 4). Kaplan-Meier curves for over-
all tumor group and the above subgroups according to
PTPRO methylation are shown in Figure 2. As shown,
tumor tissue PTPRO methylation was associated with sig-
nificantly worse cancer-specific survival in the overall
tumor group (log-rank test P = 0.0001; Figure 2a). Subgroup
analysis revealed that PTPRO methylation also showed sig-
nificant prognostic value within the ER + (P = 0.0001), PR +
(P = 0.007), and HER2-amplified (P = 0.003) patient groups
(Figure 2b, c, and d, respectively).
To confirm the significance of this finding, we per-
formed multivariate analysis, treating methylated-PTPRO
as a factor with tumor size, lymph node metastasis, histo-
logical grade, stage, HER2 status and TP53 status for their
impact on overall survival. After adjustment for these con-
variates, methylated-PTPRO was identified as an inde-
pendent predictor for overall survival in all tumor group
(hazard ratio (HR): 2.7; 95% CI: 1.1-6.2; P = 0.023) and
HER2+ subpopulation (hazard ratio (HR): 7.5; 95% CI:
1.8-31.3; P = 0.006), but not in ER + and PR + subpopula-
tion. Similarly, lymph node metastasis also had an inde-
pendent association with overall survival in this patient
series. We also analyzed the potential prognostic value of
plasma PTPRO methylation but no significant data were
obtained.
PTPRO expression is inversely correlated with
methylation status
We next sought to determine the relationship between
PTPRO methylation and gene expression in a panel ofTable 4 Univariate and multivariate cox proportional hazard
Variable Un
Hazard ratio
Tumor size (large vs small) 2.4
Lymph node status (pos. vs neg.) 4.9
Histological grade (poor vs well) 2.1
Stage (III vs I/II) 3.2
HER2 status (amp. vs wildtype) 2.2
TP53 (mutant vs wildtype) 2.3
Tumor tissue PTPRO methylation (yes vs no) 3.8
ER + group tumor tissue PTPRO methylation (yes vs no) 3.9
PR + group tumor tissue PTPRO methylation (yes vs no) 3.1
HER2+ group tumor tissue PTPRO methylation (yes vs no) 5.0breast cancer cell lines (MCF-7, MDA-MB-231, and
Hs578t) and in normal human mammary epithelial cells
(HMEC, 48R). In normal mammary epithelial cells, PTPRO
is expressed at appreciable levels and its promoter region is
not methylated; in contrast, PTPRO expression was rela-
tively low in two (MCF-7, MDA-MB-231) of the three
breast cancer cell lines examined and its promoter was
methylated (Figure 3a, b).
We performed bisulfite genomic sequencing from ten
pairs of breast tumor tissue and matched normal tissue,
one representative HMEC (48R), and one breast cancer
cell line (MCF-7) to determine if the CpG Island located
in the promoter of PTPRO was differentially methylated.
Complete bisulfite conversion was confirmed by the pres-
ence of substituted thymine for all cytosine residues at
non-CpG sites. We detected hypermethylation of CpGs in
both PTPRO-silenced tumors and in MCF-7 cells. In con-
trast, the PTPRO-expressing cell line HMEC 48R and
matched normal breast tissue exhibited low levels or no
methylation of the PTPRO promoter—strongly supporting
the MSP results (Figure 3c).
To confirm that hypermethylation of the PTPRO pro-
moter was responsible for its suppression, both MCF-7 and
MDA-MB-231 cells (hypermethylated PTPRO promoter;
silenced mRNA expression) were treated with 5-AzaC at a
final concentration of 1 μM for MCF-7 cells and 2.5 μM
for MDA-MB-231 cells. Re-expression of PTPRO in both
cell lines was observed after exposure to this demethylating
agent for 72 h and 96 h, respectively (Figure 4a). Moreover,
the MSP result showed that unmethylated PTPRO alleles
increased after 5-AzaC treatment (Figure 4b). These data
further support the notion that methylation of the PTPRO
CpG island plays an important role in gene silencing.
Discussion
Although protein tyrosine kinases have long been recog-
nized as key players in oncogenesis, the role of protein
tyrosine phosphatases in the initiation and progression ofmodel for the survival of breast cancer patients
ivariate analysis Multivariate analysis
95% CI P Hazard ratio 95% CI P
1.2-4.9 0.019





1.9-7.5 0.0001 2.7 1.1- 6.2 0.023
1.7-8.7 0.001 2.8 1.0-8.4 0.060
1.2-7.4 0.012 3.2 0.8-11.9 0.091
1.8-16.8 0.010 7.5 1.8-31.3 0.006
Figure 2 Kaplan–Meier survival analysis for breast cancer patients with (solid line) PTPRO tumor methylation or without (dotted line).
(a) overall group; (b) ER+; (c) PR+; (d) HER2-amplified subgroup.
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this study, the breast cancer series investigated here for
DNA methylation is well characterized and conventional
pathological indicators, including nodal involvement, histo-
logical grade, tumor size, and stage, all show the expected
prognostic significance. PTPRO methylation was detected
in two of three breast cancer cell lines and in 53 of 98
(54%) primary human breast cancer specimens; however,
no PTPRO methylation was observed in adjacent normal
tissue. This result is within the range (52% to 81%) reported
in previous studies of human cancers [7-10,20,30]. The ra-
ther high frequency of methylation suggests that PTPRO is
a common target for epigenetic silencing in breast tumors
and that it may contribute to the development of this
tumor type. As reported previously, demethylation of the
PTPRO promoter resulted in gene re-expression [31].
These observations demonstrate growth-suppressor charac-
teristics of PTPRO that are typical of a classical tumor sup-
pressor gene.
Aberrant hypermethylation of tumor suppressor genes
is an important epigenetic event in the development and
progression of many human cancers and may serve as a
biomarker for disease detection at early stages [32-34]. In
this study, we detected PTPRO methylation in the plasma
of 34% (33/98) of patients; this value was significantlycorrelated with PTPRO methylation detected in tumor tis-
sue. Such a high correlation confirmed that peripheral
blood samples could potentially be used to assist the de-
tection and diagnosis of breast cancer. Moreover, this
assay appears to be robust and highly specific; no methyl-
ated PTPRO was detected in plasma from breast cancer
patients without primary tumor methylation or from nor-
mal healthy control peripheral blood samples. These find-
ings are consistent with results published by Huang et al.
[21] who also examined PTPRO methylation in periph-
eral blood samples from breast cancer cases. Among 24
matched plasma samples, PTPRO was aberrantly meth-
ylated in 11 (45.8%) cases. Importantly and consistent
with our findings, no methylation was observed in nor-
mal control plasma samples from 10 healthy individuals.
These data help confirm that PTPRO methylation in
plasma samples may provide a robust, specific, non-
invasive means for early detection of breast cancer.
However, the frequency of PTPRO methylation detected
in plasma was lower than in cancer tissues and less as-
sociation of methylation were found in plasma with
clnicopathological data. This might due to fewer tumors
DNA releasing in the circulation, or poor quality of
DNA when extracted from peripheral blood, whose im-
pact factors include acquisition condition, storage time,
Figure 3 PTPRO is methylated in breast cancer cell lines but not in normal breast epithelial cells. (a) Expression of PTPRO in normal
human mammary epithelial cells (48R) and human breast cancer cell lines Hs578t, MCF-7, and MDA-MB-231. Total RNA isolated from cell lines
was subjected to RT-PCR analysis using PTPRO-specific primers. 18S rRNA was used as an internal loading control. (b) MSP analysis of PTPRO
methylation status in breast cancer cell lines. HMESC48R was used as a normal control. M, methylated; U, unmethylated. (c) PTPRO CpG island
from randomly selected breast tumor tissue and its matched normal tissue; also shown are HMEC 48R and MCF-7 cells, all of which were
subjected to BS genomic sequencing. Each solid square represents a methylated cytosine and an open square represents unmethylated cytosine
in a CpG dinucleotide. Each row corresponds to a single clone. N, normal corresponding adjacent non-cancerous tissue; T, tumor tissue.
Figure 4 Re-expression of PTPRO following treatment with
5-AzaC. (a) Breast cancer cell lines MCF-7 and MDA-MB-231 were
treated with 1 μM 5-AzaC for 72 h and 2.5 μM 5-AzaC for 96 h,
respectively. Total RNA from cells was subjected to RT-PCR to amplify
PTPRO mRNA. 18S rRNA was used for normalization; (b) MSP analysis
of PTPRO methylation status in breast cancer cell lines with or
without 5-AzaC treatment. M, methylated; U, unmethylated.
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methylation from plasma may not be extremely robust.
The more standard conditions and a larger series of breast
cancer patients should be involved for more understand-
ing the molecular mechanism and clinical behavior of
these tumors, as well as provide targets for better diagno-
sis and therapy. For sure, a more robust method must be
used if this is translated to clinical application.
In agreement with You et al. [20], we found a strong cor-
relation between PTPRO methylation and tumor stage
(Table 2), with 84% of stage III tumors found to be methyl-
ated. Similar to Huang et al. [21], PTPRO methylation cor-
related with higher histological grade. The current study is
the first to report an association between PTPRO methyla-
tion and positive lymph node status and HER2 amplifica-
tion in breast cancer. We also observed more frequent
PTPRO methylation in ER-negative and PR-negative patient
groups, possibly due to the association between these fea-
tures and poor prognosis. Interestingly, Ramaswamy et al.
[10] found that positive PTPRO expression was associated
with improved response to tamoxifen; these results are con-
sistent with previous reports of protein tyrosine phosphat-
ase gene (PTPG) [35,36]. Therefore, estrogen-mediated
suppression of PTPRO and the methylation of this gene
may play important roles in estrogen-induced tumorigen-
esis. While interesting, each of the above associations with
PTPRO methylation requires confirmation in larger studies.
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teristic aggressive phenotype is linked to methylation via si-
lencing of gene expression or through other mechanisms.
The significant associations between PTPRO methyla-
tion and nodal involvement, poorly differentiated hist-
ology, stage III tumors, and HER2 amplification suggest
that PTPRO expression may be involved in breast tumor
invasion. Given these aforementioned correlations, it is
not surprising that PTPRO methylation served as a prog-
nostic indicator of worse outcome. Although PTPRO
methylation was weakly associated with ER- and PR- sta-
tus, these factors had no prognostic value in the current
tumor series (data not shown). Similar to Huang et al.
[21], unmethylated PTPRO was significantly associated
with favorable outcome in ER + and PR + subgroups, as
well as in patients with HER2 amplification. As reported,
activation of ER results in multiple downstream effects
[37]. Recent studies indicate that ERβ expression is de-
creased in human neoplastic breast tissue, suggesting that
ERβ may be an inhibitor of tumorigenesis [38-40]. For
clinically apparent tumors, the proposed tumor-associated
factors may help protect against tumor progression. Thus,
according to prior studies, inactive PTPRO might be a
stimulating factor during tumorigenesis, explain the inef-
fection of endocrine therapy and more precise subpopula-
tions could be stratified to decide whether the patients
with ER-positive need a regimen containing tamoxifen.
In a univariate model including strong prognostic fac-
tors such as nodal status, histological grade, tumor size,
stage, HER2 amplification, and TP53 mutation status,
PTPRO methylation of overall tumors, ER+, PR + and
HER2+ group was found to be predictive of poorer out-
come for breast cancer. Multivariate analysis identified
methylated-PTPRO as an independent predictor for over-
all survival (P = 0.023), expecially in HER2+ subpopulation
(P = 0.006). In contrast to our findings, Huang et al. re-
ported that PTPRO methylation only correlated with
higher histological grade but not with any other clinical
parameters assessed [21]. This could be due to differences
in sample size or to differences in sample processing. For
example, while we used fresh tumor tissue, Huang et al.
made use of formalin-fixed paraffin-embedded samples.
Despite this, the trend is still in the same direction. That
is, PTPRO methylation and low expression are associated
with worse prognostic features, especially for HER2-
positive patients. Further supporting our claim is work
from another group showing that the receptor tyrosine
kinase ErbB2/HER2 is a direct substrate of PTPRO, and
low levels of PTPRO expression correlated with reduced
survival of HER2-positive breast cancer patients [11]. This
may also help explain why plasma PTPRO methylation
was only significantly associated with HER2 amplification.
The data we present here, in conjunction with earlier
work, establish PTPRO as a likely tumor suppressor inbreast cancer. Moreover, PTPRO methylation status might
predict response to anti-HER-targeted therapies in HER2-
positive patients, even provide extensive survival benefits
or improve the efficiency of targeted drugs due to active
PTPRO. To further study, patients who receive targeted
therapy are required.
Conclusion
In summary, our results confirm that PTPRO methylation
is detected at a high frequency in breast cancer, occurring
at a higher rate than either TP53 mutation or HER2 amp-
lification. Positive associations with nodal involvement,
poorly differentiated histology, and HER2 amplification in-
dicate that PTPRO methylation may contribute to an ag-
gressive breast tumor phenotype. This was particularly
evident for ER+, PR+, and HER2-amplified breast cancer
subgroups, which all showed that PTPRO methylation in
tumor tissues was a strong prognostic factor. Methylated-
PTPRO could serve as an independent predictor for
overall survival, expecially in HER2-positive breast can-
cer patients. Changes in protein tyrosine phosphatase
activity likely play an important role in breast carcino-
genesis and may provide a useful target for the develop-
ment of novel therapies.
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